600566 Hubei Jumpcan Pharmaceutical
- 38.86
- -0.36-0.92%
Hubei Jumpcan Pharmaceutical News
Hubei Jumpcan Pharmaceutical (600566.SH): Has repurchased a total of 961,700 shares.
On June 4th, Gelonhui reported that Hubei Jumpcan Pharmaceutical (600566.SH) has cumulatively repurchased 961,700 shares through centralized bidding trading as of May 31, 2024, accounting for 0.10% of the total share capital of the company. The highest purchase price was 30.97 yuan/share, and the lowest purchase price was 27.19 yuan/share. The total amount paid was RMB 27,094,699.88 (excluding transaction fees).
Is Hubei Jumpcan Pharmaceutical Co., Ltd.'s (SHSE:600566) Recent Stock Performance Tethered To Its Strong Fundamentals?
Hubei Jumpcan Pharmaceutical's (SHSE:600566) stock is up by a considerable 11% over the past three months. Since the market usually pay for a company's long-term fundamentals, we decided to study th
Here's Why We Think Hubei Jumpcan Pharmaceutical (SHSE:600566) Might Deserve Your Attention Today
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even companies that have no revenue, no profit, and a record of falling short, can manage
Jichuan Pharmaceutical (600566.SH): Net profit of 845 million yuan in the first quarter increased 24.90% year-on-year
Gelonghui, April 19: Jichuan Pharmaceutical (600566.SH) released its report for the first quarter of 2024. During the reporting period, it achieved operating income of 2,403 billion yuan, an increase of 0.60%; net profit attributable to shareholders of listed companies of 845 million yuan, an increase of 24.90% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss of 726 million yuan, an increase of 19.83% year on year; basic earnings per share were 0.923 yuan.
These 4 Measures Indicate That Hubei Jumpcan Pharmaceutical (SHSE:600566) Is Using Debt Safely
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' It's only natural to consider a company's balance sheet wh
Jichuan Pharmaceutical (600566.SH): Proposed 2024 Employee Stock Ownership Plan
Gelonghui, April 9, 丨 Jichuan Pharmaceutical (600566.SH) announced the 2024 employee stock ownership plan. The total number of employees participating in the current employee stock ownership plan is no more than 70, and the scale of setting up the employee stock ownership plan is no more than 14.3055 million yuan. The price of the employee's shareholding plan to buy back shares is 37.78 yuan/share.
Jichuan Pharmaceutical (600566.SH): Net profit increased 30.04% year-on-year in 2023, and plans to distribute 13 yuan to 10 shares
Gelonghui, April 9, 丨 Jichuan Pharmaceutical (600566.SH) released its 2023 annual report, with operating revenue of 9.65 billion yuan, up 7.32% year on year, net profit of 2.82 billion yuan, up 30.04% year on year, after deducting non-net profit of 2.69 billion yuan, up 32.72% year on year, with basic earnings of 3.08 yuan per share. A cash dividend of 13 yuan is distributed to all shareholders for every 10 shares.
Zhongtai Securities: Q1 results are about to be implemented, gradually focus on the pharmaceutical sector and individual stocks with improved Q2 performance
Zhongtai Securities said that at present, the overall market is still at a relative bottom. After experiencing a long-term correction, the pharmaceutical sector is also at multiple bottoms in terms of fundamentals, policies, and capital, and is firmly optimistic about the pharmaceutical sector market throughout the year.
Zheshang Securities: An important new business format that is currently breaking the pharmaceutical market, the future of the CSO sector may support the growth of relevant industry targets, etc.
The Zhitong Finance App learned that Zheshang Securities released a research report stating that profitability is related to product IP ownership, product development stage, and CSO's empowerment of products. In the future, the profitability of the CSO business is expected to continue to improve as the product structure gradually matures and the proportion of its own IP products increases. At this stage, based on judging the current macroeconomic environment and the direction of continuous deepening of medical reform, the CSO sector is an important new business format for breaking the current pharmaceutical market. Changes in business trends may support the growth and profitability of the internal standards of the business format to exceed market expectations. Recommended attention: It has proven its own brand marketing capabilities, and has mature sales channels and capabilities
Hubei Jumpcan Pharmaceutical Co., Ltd.'s (SHSE:600566) Top Owners Are Private Companies With 57% Stake, While 27% Is Held by Individual Investors
Key Insights Significant control over Hubei Jumpcan Pharmaceutical by private companies implies that the general public has more power to influence management and governance-related decisions 56% of
Hubei Jumpcan Pharmaceutical Co., Ltd.'s (SHSE:600566) Share Price Boosted 27% But Its Business Prospects Need A Lift Too
Hubei Jumpcan Pharmaceutical Co., Ltd. (SHSE:600566) shareholders would be excited to see that the share price has had a great month, posting a 27% gain and recovering from prior weakness. Looking
Jichuan Pharmaceutical (600566.SH): A total of 961,700 shares have been repurchased
Gelonghui, March 1, 丨 Jichuan Pharmaceutical (600566.SH) announced that as of February 29, 2024, the company had repurchased a total of 961,700 shares through centralized bidding transactions, accounting for 0.10% of the company's total share capital. The highest purchase price was 30.97 yuan/share, the lowest price was 27.19 yuan/share, and the total amount paid was RMB 27,094,699.88 (not including transaction fees).
Hubei Jumpcan Pharmaceutical Co., Ltd.'s (SHSE:600566) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Hubei Jumpcan Pharmaceutical (SHSE:600566) has had a great run on the share market with its stock up by a significant 18% over the last three months. Given that the market rewards strong financials
Investors in Hubei Jumpcan Pharmaceutical (SHSE:600566) Have Seen Favorable Returns of 69% Over the Past Three Years
By buying an index fund, you can roughly match the market return with ease. But if you choose individual stocks with prowess, you can make superior returns. Just take a look at Hubei Jumpcan Pharmac
Jichuan Pharmaceutical (600566.SH): A total of 961,700 shares have been repurchased as of January 31
Gelonghui, January 31, 丨 Jichuan Pharmaceutical (600566.SH) announced that as of January 31, 2024, the company had repurchased a total of 961,700 shares through centralized bidding transactions, accounting for 0.10% of the company's total share capital. The highest purchase price was 30.97 yuan/share, the lowest price was 27.19 yuan/share, and the total amount paid was RMB 27,094,699.88 (not including transaction fees).
Jichuan Pharmaceutical (600566.SH): A total of 731,500 shares have been repurchased
Gelonghui, January 2, 丨 Jichuan Pharmaceutical (600566.SH) announced that as of December 31, 2023, the company had repurchased a total of 731,500 shares through centralized bidding transactions, accounting for 0.08% of the company's total share capital. The highest purchase price was 27.75 yuan/share, the lowest price was 27.19 yuan/share, and the total amount paid was RMB 20,095,644.00 (not including transaction fees).
Should You Be Adding Hubei Jumpcan Pharmaceutical (SHSE:600566) To Your Watchlist Today?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to investors, even if it currently lacks a track record of revenue and profit. But the
Jichuan Pharmaceutical (600566.SH): In recent years, OTC channel sales of products such as Putilan anti-inflammatory oral liquid, pediatric soybean curing granules, and Huanglong cough relief granules have continued to grow rapidly
Gelonghui, December 14|Jichuan Pharmaceutical (600566.SH) stated at the “Entering Listed Companies” event that the company set up a retail division in 2021, formed a specialized team to operate OTC channels, established a business-oriented management system, and used the advantages of omni-channel mutual empowerment to form a mesh sales pattern. In recent years, OTC channel sales of products such as Putilan anti-inflammatory oral liquid, black bean curing tablets for children, and Huanglong cough relief granules have continued to grow rapidly.
Private Companies Account for 57% of Hubei Jumpcan Pharmaceutical Co., Ltd.'s (SHSE:600566) Ownership, While Individual Investors Account for 25%
Key Insights Hubei Jumpcan Pharmaceutical's significant private companies ownership suggests that the key decisions are influenced by shareholders from the larger public 56% of the business is held
Hubei Jumpcan Pharmaceutical Co., Ltd.'s (SHSE:600566) Stock Is Going Strong: Is the Market Following Fundamentals?
Hubei Jumpcan Pharmaceutical's (SHSE:600566) stock is up by a considerable 18% over the past month. Since the market usually pay for a company's long-term fundamentals, we decided to study the compa
Analysis
Price Target
No Data
